Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
80.69
-0.30 (-0.37%)
At close: Nov 7, 2025, 4:00 PM EST
80.71
+0.02 (0.02%)
After-hours: Nov 7, 2025, 6:03 PM EST
Inhibrx Biosciences Revenue
Inhibrx Biosciences had revenue of $1.30M in the quarter ending June 30, 2025, with 1,200.00% growth. This brings the company's revenue in the last twelve months to $1.40M, down -24.45% year-over-year. In the year 2024, Inhibrx Biosciences had annual revenue of $200.00K, down -88.89%.
Revenue (ttm)
$1.40M
Revenue Growth
-24.45%
P/S Ratio
834.88
Revenue / Employee
$8,696
Employees
161
Market Cap
1.17B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 200.00K | -1.60M | -88.89% |
| Dec 31, 2023 | 1.80M | 485.00K | 36.88% |
| Dec 31, 2022 | 1.32M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionINBX News
- 3 days ago - Inhibrx Announces Participation in Upcoming Scientific Conferences - PRNewsWire
- 14 days ago - Inhibrx: Positive Ozekibart Data For Bone Cancer Leads To Q2 2026 BLA Filing - Seeking Alpha
- 15 days ago - Inhibrx shares surge after bone cancer drug slows disease progression in trial - Reuters
- 15 days ago - Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts - PRNewsWire
- 16 days ago - Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts - PRNewsWire
- 3 months ago - Inhibrx Reports Second Quarter 2025 Financial Results - PRNewsWire
- 6 months ago - Inhibrx Reports First Quarter 2025 Financial Results - PRNewsWire
- 7 months ago - Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President - PRNewsWire